GlaxoSmithKline Poaches New CSO From Google's Calico
Dr Barron was Executive VP, Head of Global Product Development, and CMO of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. Source: BioSpace
Recipharm to End Operations at Two Swedish Facilities, 225 Employees Affected
The company will explore opportunity to close facilities during second half of 2019. Source: BioSpace
German Biotech InflaRx Snags $100M in IPO
The company announced the pricing of its initial public offering of 6,667,000 common shares at an initial public offering price of $15.00 per common share. Source: BioSpace
After $40M Financing, Exonics Therapeutics to Start Hiring for Cambridge Lab
The cash will allow the company to hire scientists to conduct preclinical research into a potential treatment for DMD. Source: BioSpace
J&J Exec Reveals How You Can Stand Out Among 3,000 Job Seekers
Once upon a time, before the internet, you typically heard of a job through your local newspaper. Source: BioSpace
Survey Shows Companies Aim to Increase Range of Patient Data in Clinical Trials
Most life sciences companies plan to significantly step up their use of real-world data sources over the next three years, according to a new survey by the Tufts Center for…
FDA Takes Aim at Branded Drugmakers’ Delaying Tactics on Shared REMS
The FDA is working to prevent manufacturers of branded high-risk drugs from stalling an application for approval of a generic competitor via manipulation of a requirement to share safety programs,…
Gottlieb to Delayers of Generics: ‘End the Shenanigans’
FDA Commissioner Scott Gottlieb once again chastised brand-name companies that slow-walk federal procedures and use regulations to delay the entry of generic competitors. Source: Drug Industry Daily
Bay Area's Tricia Closes $57.5M Series D, Pushes Into Phase III Trial
Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101. Source: BioSpace
Hedge Fund Takes Another Shot at Biotech, This Time at Prothena
Kerrisdale believes that Prothena's lead drug NEOD001 will fail in its current Phase 2b and Phase 3 trials. Source: BioSpace
- Go to the previous page
- 1
- …
- 264
- 265
- 266
- 267
- 268
- 269
- 270
- …
- 610
- Go to the next page